Equillium (NASDAQ:EQ – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports.
Equillium Trading Down 7.0%
EQ stock traded down $0.10 during trading on Thursday, hitting $1.32. 163,581 shares of the stock traded hands, compared to its average volume of 461,014. The stock has a market cap of $83.70 million, a price-to-earnings ratio of -6.60 and a beta of 2.08. Equillium has a one year low of $0.76 and a one year high of $3.54. The company has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $2.08.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Equillium from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Clear Str upgraded Equillium to a “strong-buy” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a report on Monday, September 21st. Zacks Research upgraded shares of Equillium from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Leerink Partners started coverage on Equillium in a research note on Monday, October 12th. They set an “outperform” rating and a $6.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.57.
View Our Latest Analysis on EQ
Equillium Company Profile
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.
Read More
- Five stocks we like better than Equillium
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.
